The Race To Develop A Coronavirus Vaccine
The Race To Develop A Coronavirus Vaccine-the growing coronavirus outbreak is causing chaos in global financial markets it’s freezing supply chains.
it’s causing companies all over the world to create work from home plans and banned business travel in late January 2020 Develop A Coronavirus Vaccine. Chinese scientists in Shanghai released the fully sequenced genome of the novel coronavirus.
that was wreaking havoc in Hebei province that kicked off the race at drug companies and government labs to develop a cure for coronavirus or at least its symptoms in terms of vaccines.
the US has moved at a pace we have never seen before still, it’s going to be at least a year to a year and a half until they have a vaccine broadly available to deploy. first off the coronavirus was hearing about on a 24/7 basis these days.
belongs to a larger family of coronaviruses that family of viruses includes the one that caused the SARS outbreak in 2002 and Middle East respiratory syndrome to spring up in 2012.
the official name of the new coronavirus is severe acute respiratory syndrome coronavirus – or SARS Cove – the one discovered in December 2019 in Wuhan China causes a disease that scientists decided to call CO vid 19 this naming convention works the same way with HIV and AIDS.
so HIV is the virus that causes AIDS the disease symptoms of Kovan 19 include fever fatigue and coughing some people become infected but don’t develop any symptoms most people around 80% recover without any special treatment.
about 1 in 6 people with the disease end up developing a serious illness older people in those with underlying medical conditions are most likely to come down with serious issues the disease. travels through small droplets that spread when people cough or sneeze those droplets land on objects people.
who touch those objects and then touch their eyes nose or mouth that’s how people catch the new coronavirus and there’s no vaccine to prevent them from getting it there’s no vaccine for any of the coronaviruses.
for that matter here’s why vaccines have become a big market for drug companies scientists and researchers no longer give them away like they used to with the polio vaccine. vaccines have become a thirty-five billion-dollar market their strong and steady demand for vaccines against established diseases like polio measles and hepatitis creating vaccines for emergency pandemics becomes tricky.
unfortunately developing vaccines and medicines for these kinds of emergency outbreak situations is not good business. we’ve seen that over history in Ebola companies haven’t necessarily been rewarded for developing vaccines and treatments.
there at least not by Wall Street and Zika we haven’t seen anything and SARS. which happened back at the beginning of the turn of the century we still don’t have anything this is not a business model that appeals to investors in the drug industry. because these are not large chronic disease drugs that bring in a lot of money they’re used.
hopefully for a short period of time to address a problem that then we hope to be able to move past so it’s not a big moneymaker for the industry and they’re very hard to predict flu vaccines.
for example, are grown in chicken eggs yes your flu shot comes from chicken eggs a lot of them that’s been the process for the last 70 years or so this process takes a long time and it’s not as reliable as newer methods like incubating vaccines and cells as opposed to eggs.
more than 100 national influenza centers in more than 100 countries monitor the flu throughout the year and make recommendations on how to create that season’s flu vaccines government agencies like the biomedical Advanced Research and Development Authority.
called Barda for short are pushing to modernize the way u.s. produces emergency vaccines like the flu shot fart is giving grants worth hundreds of millions of dollars to companies. like Sanofi which uses recombinant DNA not chicken eggs to produce flu vaccines one of its main jobs is to help.
create a market for drug companies to develop emergency vaccines through the use of its grants in late January 2020 HSS secretary Alex declared an emergency and response to the coronavirus outbreak as part of that Barda announced.
it was expanding established partnerships with snow feet and Johnson & Johnson to help develop vaccines for the coronavirus there’s an international group pouring money into the backseat freeze the Coalition for epidemic preparedness innovations it’s backed by the Bill and Melinda Gates Foundation as well as the governments of Germany Japan and Norway. it’s a relative newcomer to the global vaccine community.
it was created in 2017 to help speed up the process of developing new vaccines so far it’s invested about twenty-three point seven million dollars in the push to develop a coronavirus vaccine. it plans to invest a total of 100 million dollars in order to get vaccine candidates to early-stage clinical trials the Oslo based global coalition says it needs about two billion dollars.
more in additional funding to fully develop viable vaccines against the coronavirus most of the biotech companies working on vaccines or treatments already had a head start by previously working on SARS and Middle East respiratory syndrome which is part of the coronavirus family.
biotech firm Moderna has one of the most promising starts so far it’s using a new technique called messenger RNA or mRNA to develop its vaccine candidate the drugmaker has already started to deliver. its vaccine to national health officials the vaccine was co-designed with the National Institute of Allergy and Infectious.
Diseases after Chinese scientists decoded the coronaviruses genetic sequence in January 2020 Moderne set a record within the drug industry for the speed at which it developed its vaccine candidate using its mRNA method it took Moderna about 42 days after the coronaviruses genome was sequenced for comparison.
it took about 20 months to develop a vaccine to the human testing phase during the SARS outbreak in 2002. Moderna plans to start a small-scale human trial of the vaccine soon in Seattle Washington an epicenter of the coronavirus outbreak in the United States it will take about three months or more to show that it is safe and then.
if you show that it’s safe you’ve got to put it into what’s called a phase 2 trial to show that it works and the reason is there’s a medical ethical and other.
considerations are that we’d be giving this to normal people to prevent infection so you must be sure the the the Edict of Medicine first do no harm so we need to make sure it’s safe and we make needs to make sure it works.
that entire process will take at least a year in a year and a half Johnson & Johnson is also in the race the company is working with Barda on a potential treatment. but it’s also developing a vaccine using a deactivated version of the coronavirus as mentioned earlier.
Sanofi is also working with Barda on a coronavirus vaccine it plans to have a vaccine candidate to test in a lab within six months and on people within a year to eighteen months. but approval could be as long as three years away inovio Pharmaceuticals partnered with a Chinese company called Beijing at vaison biotechnology to speed up the development of its DNA vaccine.
received an initial grant of nine million dollars from the Coalition for epidemic preparedness innovations in Opio is using the same method for the coronavirus vaccine as it did with its DNA vaccine against the Middle East respiratory syndrome currently there haven’t been any DNA vaccines approved for use on humans doctors and global health experts.
have tried to temper vaccine expectations saying that even though this stage has gone quickly reviewing test results in getting a vaccine deployed to the public could. take many more months or even years a year to 18 months would still be the fastest we’ve ever seen a vaccine get developed and the way that breaks down right now for the lead program is that it is starting phase 1 clinical trials in people.
now it’ll take about 3 to 4 months. they say to determine the safety of the vaccine then they’re gonna move into phase 2 which will involve a lot more people and remember. these are healthy people that they’re giving the vaccine to see if it can prevent disease so the risk tolerance is low lower than.
if people were already sick and you’re giving them treatment so that’s why you have to be so careful here they say it could take perhaps eight months to get through phase two and so that’s how you’re getting out to about a year before you even know.
if you have something that’s safe and that works to protect people other drug companies are hurrying to develop various treatments for the coronavirus and them could come much sooner than vaccines the most promising according to the World Health Organization is Gilead and it’s drug rum disappear that drug is already being tested at the epicenter of the outbreak in Wuhan China and a lead is now expanding to other countries.
including the United States on a compassionate host basis, we should know within a period of a few months several months whether or not this particular drug works, if it does the implementation of that.
would be almost immediate the pressure to develop a coronavirus vaccine. grows each day as the number of infected people rises and the death toll climbs even higher but there’s a real risk to pushing too hard and too fast some drug companies plan.
to push testing schedules into human trials rather than spending months testing the vaccines on animals in labs that could lead to what’s called immune enhancement where a person or animal. who receives a vaccine ends up with a more serious disease than unvaccinated subjects according to Reuters leading health and drug companies.
officials recently advocated for fast-tracking human testing of coronavirus vaccines during a closed-door meeting convened by the World Health Organization. the question facing health officials is accelerating testing schedules worth these kinds of risks that all depend on whether countries. like the United States can contain the fast-spreading novel coronavirus.